MeSH term
Frequency | Condition_Probility | Animals | 64 | 0.0 |
Humans | 128 | 0.0 |
Cell Line, Tumor | 5 | 0.0 |
Octreotide/*pharmacology | 4 | 18.0 |
Receptors, Somatostatin/metabolism | 5 | 27.0 |
Research Support, U.S. Gov't, P.H.S. | 37 | 0.0 |
Blotting, Northern | 6 | 0.0 |
Cell Division/drug effects | 6 | 0.0 |
Gene Expression Regulation, Neoplastic/*drug effects | 2 | 0.0 |
Receptors, Somatostatin/*agonists | 2 | 100.0 |
Research Support, Non-U.S. Gov't | 84 | 0.0 |
Somatostatin/*metabolism/pharmacology | 2 | 100.0 |
Tumor Cells, Cultured | 24 | 0.0 |
Adenylate Cyclase/metabolism | 3 | 2.0 |
Cell Line | 17 | 0.0 |
Cell Membrane/metabolism | 4 | 0.0 |
Cyclic AMP/metabolism | 5 | 0.0 |
Hamsters | 9 | 0.0 |
Phosphorylation | 2 | 0.0 |
Protein Binding | 3 | 0.0 |
Receptors, Somatostatin/*metabolism | 11 | 45.0 |
Signal Transduction | 13 | 0.0 |
Somatostatin/*metabolism | 3 | 13.0 |
Time Factors | 2 | 0.0 |
Adult | 33 | 0.0 |
Aged | 31 | 0.0 |
Female | 46 | 0.0 |
*Gene Expression | 8 | 0.0 |
In Situ Hybridization | 5 | 0.0 |
Male | 40 | 0.0 |
Middle Aged | 34 | 0.0 |
RNA, Messenger/analysis | 9 | 0.0 |
Cells, Cultured | 10 | 0.0 |
Comparative Study | 11 | 0.0 |
Mice | 25 | 0.0 |
Mice, Nude | 10 | 0.0 |
Tissue Distribution | 7 | 0.0 |
Octreotide/pharmacology | 6 | 24.0 |
Receptors, Somatostatin/drug effects/genetics/*metabolism | 2 | 40.0 |
Rats | 15 | 0.0 |
Blotting, Western | 3 | 0.0 |
*Gene Transfer Techniques | 2 | 0.0 |
Genetic Vectors | 4 | 0.0 |
Radiopharmaceuticals/*diagnostic use | 2 | 4.0 |
Receptors, Somatostatin/*genetics/metabolism | 5 | 55.0 |
Adenoviridae/genetics | 2 | 0.0 |
Disease Models, Animal | 3 | 0.0 |
Mice, Inbred BALB C | 3 | 0.0 |
Neoplasm Transplantation | 5 | 0.0 |
Octreotide/*analogs & derivatives/diagnostic use | 2 | 100.0 |
In Vitro | 6 | 0.0 |
Gene Therapy/*methods | 2 | 0.0 |
Cell Survival/drug effects | 3 | 0.0 |
RNA, Messenger/genetics/metabolism | 3 | 0.0 |
Receptors, Somatostatin/genetics | 2 | 40.0 |
Reverse Transcriptase Polymerase Chain Reaction | 9 | 0.0 |
Adolescent | 6 | 0.0 |
Child | 4 | 0.0 |
DNA Primers/chemistry | 2 | 0.0 |
RNA, Messenger/*metabolism | 2 | 0.0 |
Amino Acid Sequence | 21 | 0.0 |
Base Sequence | 20 | 0.0 |
DNA Primers/genetics | 2 | 0.0 |
GTP-Binding Proteins/metabolism | 6 | 2.0 |
Molecular Sequence Data | 33 | 0.0 |
*Mutation | 2 | 0.0 |
Receptors, Somatostatin/*genetics/*physiology | 2 | 100.0 |
Somatostatin/pharmacology | 5 | 10.0 |
Gene Expression | 8 | 0.0 |
Receptors, Somatostatin/genetics/*metabolism | 6 | 46.0 |
Aminoquinolines/pharmacology | 2 | 22.0 |
Dopamine Agonists/pharmacology | 2 | 11.0 |
Oligopeptides/pharmacology | 5 | 2.0 |
Piperazines/pharmacology | 5 | 4.0 |
Prolactin/antagonists & inhibitors/secretion | 2 | 66.0 |
Adenoma/*secretion | 2 | 7.0 |
Dose-Response Relationship, Drug | 4 | 0.0 |
Human Growth Hormone/antagonists & inhibitors/*secretion | 2 | 66.0 |
Receptors, Somatostatin/drug effects/*physiology | 2 | 100.0 |
Somatostatin/*analogs & derivatives/*pharmacology | 4 | 44.0 |
Aged, 80 and over | 11 | 0.0 |
Antineoplastic Agents, Hormonal/therapeutic use | 2 | 4.0 |
Indium Radioisotopes/diagnostic use | 4 | 22.0 |
Neuroendocrine Tumors/*metabolism/radionuclide imaging | 2 | 100.0 |
Octreotide/therapeutic use | 2 | 15.0 |
Cell Division | 6 | 0.0 |
Peptides, Cyclic/pharmacology | 4 | 11.0 |
Receptors, Somatostatin/*physiology | 4 | 66.0 |
Somatostatin/*analogs & derivatives/pharmacology | 3 | 25.0 |
Thymidine/metabolism | 2 | 0.0 |
Receptors, Somatostatin/*genetics | 11 | 40.0 |
Phenotype | 2 | 0.0 |
Somatostatin/metabolism | 5 | 10.0 |
Octreotide/*therapeutic use | 2 | 5.0 |
Prolactin/secretion | 2 | 1.0 |
RNA, Messenger/metabolism | 10 | 0.0 |
Peptide Fragments/pharmacology | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 7 | 0.0 |
Gene Expression/physiology | 2 | 0.0 |
Kidney/cytology | 2 | 1.0 |
Protein Structure, Tertiary | 2 | 0.0 |
Receptors, Somatostatin/chemistry/genetics/*metabolism | 2 | 50.0 |
Neoplasm Staging | 2 | 0.0 |
Radioligand Assay | 4 | 0.0 |
Receptors, Somatostatin/*biosynthesis | 6 | 85.0 |
Gene Expression Regulation, Neoplastic | 5 | 0.0 |
Immunohistochemistry | 11 | 0.0 |
Receptors, Somatostatin/*genetics/*metabolism | 3 | 100.0 |
RNA, Messenger/genetics | 5 | 0.0 |
Receptors, Somatostatin/classification/*metabolism | 2 | 66.0 |
Pancreatic Neoplasms/metabolism/*pathology | 2 | 6.0 |
Protein Isoforms/metabolism | 2 | 1.0 |
Kinetics | 6 | 0.0 |
Molecular Structure | 2 | 0.0 |
Recombinant Proteins/metabolism | 5 | 0.0 |
Structure-Activity Relationship | 4 | 0.0 |
Acromegaly/*metabolism | 2 | 13.0 |
Hormones/pharmacology | 2 | 4.0 |
Somatostatin/analogs & derivatives/pharmacology | 2 | 50.0 |
*Chromosomes, Human, Pair 17 | 2 | 0.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
Polymerase Chain Reaction | 10 | 0.0 |
English Abstract | 3 | 0.0 |
Antibodies, Monoclonal/pharmacokinetics/*therapeutic use | 2 | 33.0 |
Copper Radioisotopes/pharmacokinetics | 2 | 100.0 |
Isotope Labeling | 2 | 2.0 |
Neoplasms, Experimental/*radiotherapy | 2 | 40.0 |
Octreotide/pharmacokinetics | 2 | 66.0 |
*Radioimmunotherapy | 2 | 7.0 |
Mutation | 3 | 0.0 |
Pituitary Neoplasms/*metabolism | 2 | 5.0 |
RNA, Messenger/*analysis | 4 | 0.0 |
Receptors, Somatostatin/*genetics/physiology | 2 | 100.0 |
Transfection | 6 | 0.0 |
Transplantation, Heterologous | 3 | 0.0 |
Nerve Tissue Proteins/*metabolism | 2 | 0.0 |
Lymphatic Metastasis/prevention & control | 2 | 66.0 |
Injections, Intramuscular | 2 | 1.0 |
Substrate Specificity | 3 | 0.0 |
Receptors, Somatostatin/*analysis/genetics | 3 | 100.0 |
Polymerase Chain Reaction/methods | 5 | 0.0 |
Transcription, Genetic | 3 | 0.0 |
Receptors, Somatostatin/*analysis | 3 | 37.0 |
Receptors, Somatostatin/*drug effects | 2 | 66.0 |
Growth Hormone/*secretion | 2 | 1.0 |
DNA Primers | 5 | 0.0 |
Radionuclide Imaging | 2 | 14.0 |
Blotting, Southern | 3 | 0.0 |
RNA, Messenger/biosynthesis | 2 | 0.0 |
Receptors, Somatostatin/classification/genetics/*physiology | 2 | 100.0 |
Somatostatin/*analogs & derivatives/*therapeutic use | 2 | 50.0 |
Calcium/*metabolism | 2 | 0.0 |
Pertussis Toxin | 7 | 4.0 |
Somatostatin/*pharmacology | 2 | 4.0 |
Tumor Cells, Cultured/metabolism | 2 | 1.0 |
Virulence Factors, Bordetella/pharmacology | 7 | 3.0 |
Binding, Competitive | 3 | 0.0 |
Octreotide/metabolism | 2 | 50.0 |
Cloning, Molecular | 14 | 0.0 |
*Transcription, Genetic | 2 | 0.0 |
Autoradiography | 4 | 0.0 |
DNA, Complementary | 2 | 0.0 |
Somatostatin/metabolism/pharmacology | 3 | 50.0 |
Sequence Alignment | 2 | 0.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
*Signal Transduction | 3 | 0.0 |
Ligands | 2 | 0.0 |
GTP-Binding Proteins/physiology | 2 | 3.0 |
CHO Cells | 6 | 0.0 |
Adenylate Cyclase Toxin | 6 | 25.0 |
DNA, Complementary/genetics | 2 | 0.0 |
Protein-Tyrosine-Phosphatase/*metabolism | 2 | 1.0 |
Brain/metabolism | 2 | 0.0 |
RNA, Messenger/analysis/biosynthesis | 2 | 0.0 |
Cyclic AMP/biosynthesis | 2 | 1.0 |
Forskolin/pharmacology | 2 | 0.0 |
Receptors, Somatostatin/classification/genetics/*metabolism | 2 | 40.0 |
DNA | 2 | 0.0 |
RNA, Messenger/analysis/genetics | 2 | 0.0 |
*Chromosomes, Human, Pair 22 | 2 | 0.0 |
Haplorhini | 2 | 0.0 |
*Gene Expression Regulation | 2 | 0.0 |
DNA/genetics | 2 | 0.0 |
Receptors, Somatostatin | 2 | 13.0 |
Human Growth Hormone/*secretion | 3 | 7.0 |
Prolactin/*secretion | 2 | 1.0 |
Pituitary Gland/drug effects/*metabolism | 2 | 33.0 |
Biopsy | 2 | 0.0 |
